Ulinastatin's Anti-inflammatory Reaction in Cardiac Surgery
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the present study is to determine whether ulinastatin, urinary anti-trypsin
inhibitor, attenuates cardiopulmonary bypass (CPB)-activated systemic inflammatory response
in cardiac surgery with CPB.
Serial measurements and analysis of several inflammatory cytokines (bactericidal permeability
increasing protein, interleukin-6, tumor necrosis factor-α)as well as markers of cardiac
injury, renal impairment and oxygenation profile will be performed to determine ulinastatin's
efficacy.